417717-20-5

Basic information

• Product Name: Lenvatinib Impurity e
• Synonyms: Lenvatinib Impurity e;methyl 4-(3-chloro-4-(3-cyclopropylureido)phenoxy)-7-methoxyquinoline-6-carboxylate;4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxylic acid methyl ester
• CAS NO: 417717-20-5
• Molecular Formula: C₂₂H₂₀ClN₃O₅
• Molecular Weight: 441.8643
• Mol File: 417717-20-5.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 592.0±50.0 °C(Predicted)
• Appearance: /
• Density: 1.42±0.1 g/cm3(Predicted)
• PKA: 13.08±0.70(Predicted)
• CAS DataBase Reference: Lenvatinib Impurity e(CAS DataBase Reference)
• NIST Chemistry Reference: Lenvatinib Impurity e(417717-20-5)
• EPA Substance Registry System: Lenvatinib Impurity e(417717-20-5)

Safety Data

• Hazardous Substances Data: 417717-20-5(Hazardous Substances Data)

Usage

General Description

Lenvatinib Impurity e, also known as (3Z)-5-[(1E)-2-(3,4-dimethoxyphenyl)ethenyl]-3-[(2R,4R)-4-ethyl-4,5-dihydro-1,3-oxazol-2-yl]imidazolidine-2,4-dione, is a potentially genotoxic impurity found in the drug substance Lenvatinib. It is a heterocyclic compound containing an imidazolidine-2,4-dione core and an oxazol group. This impurity can pose a risk to human health and requires thorough characterization and control to ensure the safety and efficacy of the Lenvatinib drug product. Therefore, it is important for pharmaceutical companies to monitor and limit the presence of Lenvatinib Impurity e in their manufacturing processes.

Upstream product

• 796848-79-8 1-(2-chloro-4-hydroxyphenyl)-3-cyclopropyl urea 
• 205448-66-4 methyl 4-chloro-7-methoxyquinoline-6-carboxylate 
• 205448-65-3 7-methoxy-4-oxo-1,4-dihydroquinoline-6-carboxylic acid methyl ester 
• 417723-09-2 phenyl N-(2-chloro-4-(7-methoxy-6-methoxycarbonyl-4-quinolyl)oxyphenyl)carbamate 
• 765-30-0 Cyclopropylamine 

Downstream Products

• 417717-21-6 4-[3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy]-7-methoxyquinoline-6-carboxylic acid 

Relevant articles and documents

Lenvatinib-zinc phthalocyanine conjugates as potential agents for enhancing synergistic therapy of multidrug-resistant cancer by glutathione depletion

The therapeutic efficacy of targeted therapy is dramatically hindered by multidrug resistance (MDR) because of elevated GSH levels. Thus, depletion of intracellular GSH level is highly desirable for targeted-therapeutic agents to reverse tumor drug resist

Nitrogen-containing aromatic derivatives

Compounds represented by the following general formula: [wherein Ag is an optionally substituted 5- to 14-membered heterocyclic group, etc.; Xg is —O—, —S—, etc.; Yg is an optionally substituted C6-14 aryl group, an optionally substituted 5- to 14-membered heterocyclic group, etc.; and Tg1 is a group represented by the following general formula: (wherein Eg is a single bond or —N(Rg2)—, Rg1 and Rg2 each independently represent a hydrogen atom, an optionally substituted C1-6 alkyl group, etc. and Zg represents a C1-8 alkyl group, a C3-8 alicyclic hydrocarbon group, a C6-14 aryl group, etc.)], salts thereof or hydrates of the foregoing.